Advanced lipid nanoparticle formulation and evaluation services for plasmid DNA delivery.
Plasmid DNA (pDNA) delivery requires a carrier system that can condense large, negatively charged DNA structures, protect them from nuclease degradation, support cellular entry, and promote intracellular trafficking toward functional gene expression. Compared with short RNA cargos, pDNA presents distinct formulation challenges due to its larger molecular size, supercoiled or relaxed topology, shear sensitivity, and stronger dependence on ionizable lipid chemistry, helper lipid selection, and particle architecture. BOC Sciences provides specialized lipid nanoparticle (LNP) services for pDNA delivery, covering formulation design, lipid composition screening, encapsulation optimization, physicochemical characterization, release behavior profiling, and biological performance evaluation. Our integrated workflow helps pharmaceutical and biotechnology researchers identify formulation conditions that balance pDNA loading, colloidal stability, cell compatibility, and transfection efficiency for gene delivery research.
Lipid Nanoparticle pDNA Delivery ProcessBOC Sciences supports end-to-end development of lipid nanoparticles for plasmid DNA delivery, from early formulation feasibility to performance-driven optimization. Our services are designed for research teams developing non-viral gene delivery systems, reporter plasmid platforms, gene expression models, genome editing support cargos, and functional plasmid payloads for cellular and preclinical research.
We design LNP systems according to plasmid size, topology, target cell type, desired expression profile, and route-relevant biological environment. The formulation strategy can be built around ionizable lipids, helper phospholipids, cholesterol, PEG-lipids, and optional functional lipid components.
Efficient pDNA delivery begins with stable encapsulation and structural protection. We optimize lipid-pDNA complexation to reduce free DNA, minimize aggregation, and preserve plasmid integrity during formulation and storage studies.
We provide controlled formulation workflows using rapid mixing approaches suitable for nucleic acid LNP development. These workflows help generate reproducible pDNA-LNP batches while allowing systematic comparison of process variables.
pDNA delivery is highly sensitive to lipid ionization behavior and lipid-DNA interaction strength. BOC Sciences helps clients compare ionizable lipid nanoparticles and cationic lipid nanoparticles to identify systems with suitable encapsulation, stability, and transfection profiles.
For projects requiring selective cell interaction or tissue-oriented delivery research, our team can introduce surface ligands, lipid anchors, or charge-tuning strategies into pDNA-LNP systems. These designs can be connected with broader targeted LNP development workflows.
pDNA-LNP performance cannot be predicted from size or encapsulation alone. We combine physicochemical data with biological readouts to identify formulation-property relationships and guide iterative improvement.
Successful plasmid DNA delivery requires cargo-informed LNP design rather than direct transfer of RNA-LNP conditions. BOC Sciences develops formulation strategies around the physical structure of the plasmid, the lipid assembly mechanism, and the biological barriers that must be overcome after cellular uptake.
From lipid screening to expression readouts, BOC Sciences helps transform plasmid DNA into optimized lipid nanoparticle delivery systems for gene delivery research.
Our pDNA-LNP platform connects formulation preparation, analytical characterization, and functional evaluation. Each project is customized according to plasmid length, promoter system, expression reporter, target cell model, and required formulation attributes.
| Service Area | Technical Scope and Project Value |
|---|---|
| Lipid Nanoparticle Formulation | Design and preparation of pDNA-loaded LNPs using controlled lipid composition, mixing parameters, buffer systems, and pDNA input ratios. |
| Lipid Nanoparticle Encapsulation | Quantification and optimization of plasmid encapsulation efficiency, accessible DNA fraction, nuclease protection, and lipid-pDNA complex stability. |
| Lipid Nanoparticle Characterization | Integrated characterization of particle size, PDI, zeta potential, morphology, pDNA loading, lipid composition, and formulation consistency. |
| Nanoparticle Size Analysis | DLS, NTA, or complementary sizing methods to assess particle diameter, population distribution, aggregation tendency, and formulation uniformity. |
| Nanoparticle Zeta Potential Analysis | Surface charge evaluation to support colloidal stability analysis, lipid ratio optimization, and biological interaction interpretation. |
| Nanoparticle Drug Loading Analysis | Adapted loading analysis for plasmid cargo, including total pDNA content, free pDNA fraction, encapsulated pDNA fraction, and extraction recovery. |
| Nanoparticle Drug Release Services | pDNA leakage and release behavior evaluation under buffer, dilution, serum, enzyme, and stress conditions relevant to formulation screening. |
| Lipid Nanoparticle Stability | Monitoring of particle size change, aggregation, pDNA leakage, lipid degradation indicators, and freeze-thaw response during storage-oriented studies. |
| Nanoparticle Cellular Uptake Testing | Fluorescence-based or imaging-assisted uptake analysis to determine whether pDNA-LNPs efficiently enter target cells. |
| Nanoparticle Intracellular Localization Detection | Intracellular trafficking analysis to help distinguish endosomal retention, cytosolic release limitations, and nuclear availability barriers. |
| Nanoparticle In Vitro Evaluation | Reporter expression, cell viability, dose-response comparison, and cell model screening for pDNA-LNP formulation ranking. |
| Lipid Nanoparticles for Gene Delivery | Broader LNP gene delivery solutions for plasmid DNA, RNA, and other nucleic acid cargos requiring non-viral delivery system development. |
Plasmid DNA is not simply a longer RNA cargo. Its molecular size, topology, expression mechanism, and intracellular trafficking requirements create specific challenges that must be addressed during LNP design.
✔ Low pDNA Encapsulation
Large plasmids can be difficult to compact into uniform nanoparticles. We screen lipid ratios, pH conditions, and N:P ratios to improve encapsulation while avoiding oversized aggregates.
✔ Plasmid Topology Damage
Shear stress, solvent exposure, and harsh extraction can shift supercoiled plasmids toward nicked or linear forms. We adjust mixing, purification, and analytical protocols to protect plasmid structure.
✔ Aggregation During Buffer Exchange
pDNA-LNPs may aggregate during ethanol removal or concentration. We optimize dilution rate, buffer composition, PEG-lipid content, and ionic strength to preserve colloidal stability.
✔ Poor Transfection Despite High Uptake
Uptake does not guarantee expression. We combine uptake testing, intracellular localization, and reporter expression to determine whether the limiting step is entry, endosomal escape, or downstream trafficking.
✔ Serum-Induced pDNA Leakage
Protein-rich media can destabilize lipid assemblies and expose plasmid cargo. We use serum challenge assays and nuclease protection testing to compare formulation robustness.
✔ Formulation-Dependent Cell Response
Lipid charge, helper lipid ratio, and particle concentration can affect cell tolerance. We evaluate expression together with cell viability to avoid misleading formulation rankings.
We review plasmid size, topology, concentration, buffer background, reporter system, target cell model, and desired formulation attributes. This information guides lipid selection, analytical design, and performance evaluation strategy.
We prepare pDNA-LNP libraries by varying lipid composition, N:P ratio, flow rate ratio, buffer pH, and purification conditions. Candidate formulations are ranked by size, PDI, encapsulation, and early stability behavior.
Selected formulations undergo particle characterization, pDNA integrity assessment, nuclease protection testing, cellular uptake analysis, reporter expression testing, and cell compatibility evaluation.
We deliver a structured report summarizing formulation composition, preparation conditions, analytical results, expression readouts, comparative ranking, and recommended next-step optimization directions.
Challenge: A biotechnology research team was developing a luciferase reporter plasmid LNP for a hard-to-transfect adherent cell model. Their initial formulation showed acceptable particle size around 120 nm and high apparent pDNA encapsulation, but reporter expression remained weak and cell viability decreased at higher lipid doses.
Diagnosis: BOC Sciences compared three ionizable lipid systems, two helper lipid ratios, and PEG-lipid contents between 0.5 mol% and 2.0 mol%. Cellular uptake analysis showed that the original formulation entered cells efficiently, but intracellular localization imaging indicated strong endosomal retention. Zeta potential analysis also suggested excessive positive surface character after dilution into culture medium, which likely contributed to reduced cell tolerance.
Solution: We redesigned the formulation using a lower N:P ratio, increased the fusogenic helper lipid fraction, and reduced PEG-lipid shielding to improve membrane interaction after uptake. A second formulation set was prepared under milder microfluidic mixing conditions to maintain plasmid topology. The optimized candidate showed a narrower size distribution, retained most of the plasmid in supercoiled form, and improved endosomal escape indicators in the selected cell model.
Result: Among 18 tested formulations, one candidate produced a more than 6-fold increase in luciferase signal compared with the starting formulation while maintaining improved cell compatibility at the same pDNA dose. The client used the dataset to select a lead pDNA-LNP composition for expanded cell model testing.
Challenge: A drug discovery group needed to encapsulate a large expression plasmid above 8 kb into LNPs for transient gene expression studies. Their existing RNA-LNP-inspired formulation generated broad particle populations above 250 nm, visible aggregation after buffer exchange, and inconsistent plasmid recovery after lipid extraction.
Diagnosis: Our team found that the large plasmid required slower complexation kinetics than the client's original process allowed. High ionic strength during post-mixing dilution promoted aggregation, while the extraction method underestimated pDNA loading because lipid residues interfered with fluorescent dye binding. Agarose gel analysis also showed partial conversion of supercoiled plasmid into nicked forms after repeated freeze-thaw handling.
Solution: BOC Sciences screened 24 formulation and processing conditions, including modified aqueous buffer pH, lower total lipid concentration, adjusted flow rate ratio, and PEG-lipid chain-length variation. We replaced the original loading assay with a parallel workflow combining nuclease protection, detergent-assisted release, and gel-based topology assessment. For stability, we evaluated three cryoprotectant systems and identified a reconstitution condition that minimized size increase after thawing.
Result: The selected pDNA-LNP formulation achieved a particle size near 150 nm with reduced PDI, maintained strong nuclease protection, and preserved a higher supercoiled plasmid fraction after one freeze-thaw cycle. The project provided the client with a practical formulation window for larger plasmid delivery studies.
Cargo-Specific LNP DesignWe do not simply transfer mRNA or siRNA formulation logic to plasmid DNA. Our team builds pDNA-LNP systems around plasmid size, topology, condensation behavior, and expression requirements.
Integrated Formulation and TestingBOC Sciences connects preparation, encapsulation analysis, particle characterization, uptake testing, and expression evaluation so that each formulation decision is supported by multiple data layers.
Broad Lipid Platform ExperienceOur capabilities cover lipid nanoparticles, ionizable lipid systems, cationic lipid systems, solid lipid structures, and hybrid lipid-based delivery formats.
Mechanism-Oriented TroubleshootingWhen expression is weak, we investigate whether the cause is poor encapsulation, aggregation, low uptake, endosomal retention, plasmid damage, or formulation-related cell response.
Flexible Project Entry PointsWhether you need early feasibility screening, formulation rescue, analytical method development, or expanded biological evaluation, we can customize the workflow to match your project stage.
Plasmid DNA is large, highly anionic, and structurally sensitive, making it difficult to deliver efficiently without a protective carrier. Lipid nanoparticles can condense and shield pDNA through interactions with ionizable or cationic lipid components, helping reduce exposure to nucleases while improving cellular uptake. For researchers developing non-viral gene delivery systems, LNPs offer a tunable platform in which lipid composition, N/P ratio, particle size, surface charge, and buffer conditions can be adjusted to match different plasmid sizes and target cell models. The key advantage is not only protection, but also formulation flexibility for balancing encapsulation, colloidal stability, intracellular release, and expression performance.
Encapsulation efficiency is strongly influenced by the interaction between pDNA and the lipid phase during nanoparticle assembly. Important variables include the N/P ratio, ionizable lipid chemistry, helper lipid content, pDNA concentration, aqueous buffer pH, ionic strength, ethanol-to-aqueous mixing ratio, flow rate, and post-formulation processing. Because pDNA is larger and more conformationally complex than short RNA cargos, overly aggressive condensation may compromise plasmid topology, while insufficient complexation may leave a high free-pDNA fraction. BOC Sciences supports pDNA-LNP formulation screening by combining preparation optimization with particle sizing, charge analysis, fluorescence accessibility assays, and gel-based integrity checks to identify conditions that improve loading without sacrificing plasmid quality.
A robust pDNA-LNP characterization package usually includes particle size, PDI, zeta potential, morphology, encapsulation efficiency, plasmid integrity, colloidal stability, and functional expression assessment. Dynamic light scattering is commonly used to evaluate size distribution, while zeta potential helps indicate surface charge behavior. Fluorescent nucleic acid dyes can distinguish accessible pDNA from encapsulated pDNA before and after nanoparticle disruption. Agarose gel electrophoresis can reveal free plasmid, complexed plasmid, and possible structural changes in the DNA. Depending on project goals, researchers may also assess serum stability, nuclease protection, release behavior, cellular uptake, and reporter gene expression to understand whether the formulation is only physically stable or also functionally effective.
Although both pDNA-LNP and mRNA-LNP systems are lipid-based nucleic acid delivery platforms, their formulation logic is not identical. pDNA is typically larger, more rigid, and topology-dependent, while mRNA is single-stranded and more directly linked to cytoplasmic translation. pDNA delivery must account for intracellular trafficking barriers associated with nuclear access, whereas mRNA delivery primarily focuses on cytosolic release and translation efficiency. As a result, lipid ratios, mixing parameters, and release profiles optimized for mRNA may not translate directly to pDNA. pDNA-LNP development often requires more careful evaluation of plasmid condensation, endosomal escape, nuclear-associated delivery behavior, and maintenance of supercoiled plasmid structure during formulation and storage.
BOC Sciences provides integrated support for pDNA-LNP development, from formulation design and preparation to physicochemical characterization and performance-oriented evaluation. Our team can help screen ionizable lipid systems, helper lipids, cholesterol ratios, PEG-lipid levels, N/P ratios, and mixing parameters to identify formulation conditions suitable for specific plasmid sizes and application models. Analytical support may include particle size and PDI measurement, zeta potential analysis, pDNA encapsulation assessment, plasmid integrity evaluation, morphology observation, stability testing, and in vitro delivery-related studies. By connecting formulation variables with measurable data, we help researchers reduce trial-and-error and develop pDNA-LNP systems with clearer structure–performance relationships.
